| Malignant disease | |||||
|---|---|---|---|---|---|
| Malignant disease / Antibody responsive malignancy | |||||
| bevacizumab [Specialist drug] | Restricted |
NICE TA118 NICE TA212 NICE TA242 NICE TA178 NICE TA214 NICE TA263 NICE TA284 NICE TA285 NICE TA666 NICE TA946 |
|||
| Solution for infusion | |||||
| Avastin (Roche Products Ltd) | Restricted | ||||
| blinatumomab [Specialist drug] | Restricted |
NICE TA450 NICE TA589 |
|||
|
Note
On Haematology recommendations only |
|||||
| brentuximab vedotin [Specialist drug] | Restricted |
NICE TA478 NICE TA641 NICE TA524 NICE TA577 |
|||
| cetuximab [Specialist drug] | Non Formulary |
NICE TA145 NICE TA473 NICE TA242 NICE TA439 NICE TA668 |
|||
| Solution for infusion | |||||
| Erbitux (Merck Serono Ltd) | Non Formulary | ||||
| daratumumab | Restricted |
NICE TA763 NICE TA783 NICE TA897 NICE TA917 NICE TA959 |
|||
|
Note
PbRex- CDF, Hospital ONLY, Haematology Team Only Daratumumab monotherapy for treating relapsed and refractory multiple myeloma as per NICE TA 510 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma as per NICE TA573 Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable NICE TA763- JFC Feb 2022
|
|||||
| Solution for infusion | |||||
| Darzalex (Janssen-Cilag Ltd) | Restricted | ||||
| gemtuzumab ozogamicin [Specialist drug] | On Formulary |
NICE TA545 |
|||
| Powder for solution for infusion | |||||
| Mylotarg (Pfizer Ltd) | On Formulary | ||||
| ipilimumab [Specialist drug] | Non Formulary |
NICE TA268 NICE TA319 NICE TA400 NICE TA716 NICE TA724 NICE TA780 NICE TA818 |
|||
| Solution for infusion | |||||
| Yervoy (Bristol-Myers Squibb Pharmaceuticals Ltd) | Non Formulary | ||||
| obinutuzumab [Specialist drug] | Restricted |
NICE TA343 NICE TA513 NICE TA629 |
|||
| Solution for infusion | |||||
| Gazyvaro (Roche Products Ltd) | Restricted | ||||
| panitumumab [Specialist drug] | Non Formulary |
NICE TA242 NICE TA439 |
|||
| Solution for infusion | |||||
| Vectibix (Amgen Ltd) | Non Formulary | ||||
| pembrolizumab [Specialist drug] | Restricted |
NICE TA357 NICE TA366 NICE TA766 NICE TA837 NICE TA428 NICE TA531 NICE TA683 NICE TA770 NICE TA1017 NICE TA692 NICE TA772 NICE TA540 NICE TA967 NICE TA650 NICE TA830 NICE TA858 NICE TA661 NICE TA709 NICE TA914 NICE TA983 NICE TA737 NICE TA997 NICE TA801 NICE TA851 NICE TA939 NICE TA904 |
|||
|
Note
PbRex- CDF. Hospital ONLY, Haematology Team ONLY as per NICE TA 540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma Also as per TA772 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies and NICE TA772 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies JFC March 2022 |
|||||
| polatuzumab vedotin [Specialist drug] | Restricted |
NICE TA649 NICE TA874 |
|||
| rituximab | Restricted |
NICE TA308 NICE TA195 NICE TA243 NICE TA137 NICE TA193 NICE TA226 NICE TA174 NICE TA359 NICE TA561 |
|||
| Solution for infusion | |||||
| MabThera (Roche Products Ltd) | Non Formulary | ||||
| Rixathon (Sandoz Ltd) | Restricted | ||||
| Truxima (Celltrion Healthcare UK Ltd) | On Formulary | ||||
| trastuzumab [Specialist drug] | Non Formulary |
NICE TA34 NICE TA257 NICE TA509 NICE TA208 |
|||
| Solution for injection | |||||
| Herceptin (Roche Products Ltd) | Non Formulary | ||||
| Malignant disease / Immunotherapy responsive malignancy | |||||
| Bacillus Calmette-Guérin [Specialist drug] | Restricted | ||||
| Powder for reconstitution for instillation | |||||
| OncoTICE (Merck Sharp & Dohme (UK) Ltd) | Restricted | ||||
| aldesleukin [Specialist drug] | Non Formulary | ||||
| Powder for solution for injection | |||||
| Proleukin (Clinigen Healthcare Ltd) | Non Formulary | ||||
| interferon gamma-1b | Non Formulary | ||||
| Solution for injection | |||||
| Immukin (Clinigen Healthcare Ltd) | Non Formulary | ||||
| lenalidomide [Specialist drug] | Restricted |
NICE TA322 NICE TA171 NICE TA586 NICE TA587 NICE TA627 NICE TA680 |
|||
| mifamurtide [Specialist drug] | Non Formulary |
NICE TA235 |
|||
| pomalidomide [Specialist drug] | Restricted |
NICE TA427 |
|||
| thalidomide [Specialist drug] | Restricted |
NICE TA228 |
|||
| Malignant disease / Targeted therapy responsive malignancy | |||||
| acalabrutinib [Specialist drug] | Restricted |
NICE TA689 NICE TA689 |
|||
| aflibercept [Specialist drug] | Restricted |
NICE TA294 NICE TA305 NICE TA346 NICE TA409 NICE TA486 NICE TA307 |
|||
| Solution for injection | |||||
| Eylea (Bayer Plc) | Restricted | ||||
| Solution for infusion | |||||
| Zaltrap (Sanofi) | Restricted | ||||
| bortezomib [Specialist drug] | Restricted |
NICE TA370 NICE TA311 NICE TA228 NICE TA129 |
|||
| Powder for solution for injection | |||||
| Velcade (Janssen-Cilag Ltd) | Restricted | ||||
| bosutinib [Specialist drug] | Restricted |
NICE TA401 |
|||
| carfilzomib [Specialist drug] | Restricted |
NICE TA657 NICE TA695 |
|||
| dasatinib [Specialist drug] | Restricted |
NICE TA426 NICE TA425 |
|||
| erlotinib [Specialist drug] | Restricted |
NICE TA227 NICE TA258 NICE TA374 NICE TA374 |
|||
| everolimus | Non Formulary |
NICE TA421 NICE TA432 NICE TA449 |
|||
|
Afinitor® NICE TA498 Certican® NICE TA348 Certican® NICE TA481 |
|||||
| gefitinib [Specialist drug] | Non Formulary |
NICE TA192 NICE TA374 |
|||
| gilteritinib [Specialist drug] | Restricted |
NICE TA642 |
|||
| ibrutinib [Specialist drug] | Restricted |
NICE TA429 NICE TA891 NICE TA502 NICE TA795 |
|||
| idelalisib [Specialist drug] | Restricted |
NICE TA359 NICE TA604 |
|||
| imatinib [Specialist drug] | Restricted |
NICE TA326 NICE TA70 NICE TA86 NICE TA209 NICE TA426 NICE TA425 |
|||
| lapatinib [Specialist drug] | Non Formulary |
NICE TA257 |
|||
| midostaurin [Specialist drug] | Restricted |
NICE TA523 NICE TA728 |
|||
|
Note
Haematology Consultants ONLY Hospital ONLY To be prescribed as per NICE TA523 " Midostaurin for untreated acute myeloid leukaemia" and NICE TA728 "Midostaurin for treating advanced systemic mastocytosis"
|
|||||
| nilotinib [Specialist drug] | Restricted |
NICE TA426 NICE TA425 |
|||
| pazopanib [Specialist drug] | Non Formulary |
NICE TA215 |
|||
| ponatinib [Specialist drug] | Restricted |
NICE TA451 |
|||
| ruxolitinib [Specialist drug] | Restricted |
NICE TA386 NICE TA921 |
|||
| sorafenib [Specialist drug] | Non Formulary |
NICE TA178 NICE TA474 NICE TA535 |
|||
| sunitinib [Specialist drug] | Non Formulary |
NICE TA169 NICE TA179 NICE TA178 NICE TA449 |
|||
| temsirolimus [Specialist drug] | Non Formulary |
NICE TA178 |
|||
| Solution for infusion | |||||
| Torisel (Pfizer Ltd) | Non Formulary | ||||
| vandetanib [Specialist drug] | Non Formulary |
NICE TA550 |
|||
| vemurafenib [Specialist drug] | Non Formulary |
NICE TA269 |
|||
| venetoclax [Specialist drug] | Restricted |
NICE TA561 NICE TA663 NICE TA796 NICE TA765 NICE TA787 |
|||
|
Note
On formulary as per NICE TA487, TA561 and TA663, to be prescribed by Haematology Consultants only. Added to Formulary also as per TA765 Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable JFC March 2022 Hospital Only |
|||||
| Malignant disease / Cytotoxic responsive malignancy | |||||
| arsenic trioxide [Specialist drug] | Restricted |
NICE TA526 |
|||
| Solution for infusion | |||||
| Trisenox (Teva UK Ltd) | Non Formulary | ||||
| azacitidine [Specialist drug] | Restricted |
NICE TA218 NICE TA399 NICE TA827 |
|||
|
AZACITIDINE
PbR Ex - NHSE Added to Formulary also as per TA765 Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable JFC March 2022 Hospital Only |
|||||
| Powder for suspension for injection | |||||
| Vidaza (Bristol-Myers Squibb Pharmaceuticals Ltd) | Restricted | ||||
| bendamustine hydrochloride [Specialist drug] | Restricted |
NICE TA216 NICE TA472 |
|||
| bexarotene [Specialist drug] | Non Formulary | ||||
| bleomycin [Specialist drug] | Restricted | ||||
| busulfan [Specialist drug] | On Formulary | ||||
| cabazitaxel [Specialist drug] | Non Formulary |
NICE TA391 |
|||
| capecitabine [Specialist drug] | Non Formulary |
NICE TA263 NICE TA212 NICE TA191 NICE TA61 NICE TA100 |
|||
| carboplatin [Specialist drug] | Restricted |
NICE TA284 NICE TA285 |
|||
| Solution for infusion | |||||
| Carboplatin (Non-proprietary) | Restricted | ||||
| carmustine [Specialist drug] | Non Formulary |
NICE TA121 |
|||
| chlorambucil [Specialist drug] | Restricted |
NICE TA343 NICE TA344 |
|||
| cisplatin [Specialist drug] | Restricted | ||||
| Solution for infusion | |||||
| Cisplatin (Non-proprietary) | Restricted | ||||
| cladribine | Restricted |
NICE TA616 |
|||
| Solution for injection | |||||
| Litak (Lipomed GmbH) | Non Formulary | ||||
| Solution for infusion | |||||
| Leustat (Atnahs Pharma UK Ltd) | Restricted | ||||
| clofarabine [Specialist drug] | Restricted | ||||
| crisantaspase [Specialist drug] | Restricted | ||||
| Powder for solution for injection | |||||
| Erwinase (Porton Biopharma Ltd) | Restricted | ||||
| cyclophosphamide | Restricted | ||||
| Powder for solution for injection | |||||
| Cyclophosphamide (Non-proprietary) | Restricted | ||||
| cytarabine [Specialist drug] | Restricted | ||||
| Solution for injection | |||||
| Cytarabine (Non-proprietary) | Restricted | ||||
| dacarbazine [Specialist drug] | Restricted | ||||
| Powder for solution for injection | |||||
| Dacarbazine (Non-proprietary) | Restricted | ||||
| daunorubicin [Specialist drug] | Restricted | ||||
| daunorubicin with cytarabine [Specialist drug] | On Formulary |
NICE TA552 |
|||
|
Notes
As per NICE TA552 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (December 2018)
|
|||||
| docetaxel [Specialist drug] | Restricted |
NICE TA101 NICE TA509 |
|||
| Solution for infusion | |||||
| Docetaxel (Non-proprietary) | Restricted | ||||
| doxorubicin hydrochloride [Specialist drug] | Restricted |
NICE TA389 NICE TA465 |
|||
| Solution for injection | |||||
| Doxorubicin hydrochloride (Non-proprietary) | Restricted | ||||
| Solution for infusion | |||||
| Doxorubicin hydrochloride (Non-proprietary) | Restricted | ||||
| epirubicin hydrochloride [Specialist drug] | Restricted | ||||
| Solution for injection | |||||
| Epirubicin hydrochloride (Non-proprietary) | Restricted | ||||
| Pharmorubicin (Pfizer Ltd) | Restricted | ||||
| Solution for infusion | |||||
| Epirubicin hydrochloride (Non-proprietary) | Restricted | ||||
| eribulin [Specialist drug] | Non Formulary |
NICE TA423 NICE TA515 |
|||
| Solution for injection | |||||
| Halaven (Eisai Ltd) | Non Formulary | ||||
| estramustine phosphate [Specialist drug] | Restricted | ||||
| etoposide [Specialist drug] | Restricted | ||||
| Powder for solution for injection | |||||
| Etopophos (Neon Healthcare Ltd) | Restricted | ||||
| Solution for infusion | |||||
| Etoposide (Non-proprietary) | Restricted | ||||
| fludarabine phosphate [Specialist drug] | Restricted |
NICE TA119 NICE TA29 |
|||
| Solution for injection | |||||
| Fludarabine phosphate (Non-proprietary) | Restricted | ||||
| Powder for solution for injection | |||||
| Fludara (Sanofi) | Non Formulary | ||||
| fluorouracil | Restricted | ||||
| Solution for injection | |||||
| Fluorouracil (Non-proprietary) | Non Formulary | ||||
| Solution for infusion | |||||
| Fluorouracil (Non-proprietary) | Non Formulary | ||||
| gemcitabine [Specialist drug] | Restricted |
NICE TA25 NICE TA116 NICE TA285 NICE TA389 NICE TA476 |
|||
| Solution for infusion | |||||
| Gemcitabine (Non-proprietary) | Restricted | ||||
| hydroxycarbamide | On Formulary | ||||
| idarubicin hydrochloride [Specialist drug] | Restricted | ||||
| ifosfamide [Specialist drug] | Restricted | ||||
| Powder for solution for injection | |||||
| Ifosfamide (Non-proprietary) | Restricted | ||||
| irinotecan hydrochloride [Specialist drug] | Non Formulary |
NICE TA440 |
|||
| Solution for infusion | |||||
| Irinotecan hydrochloride (Non-proprietary) | Non Formulary | ||||
| Campto (Pfizer Ltd) | Non Formulary | ||||
| lomustine [Specialist drug] | Non Formulary | ||||
| melphalan [Specialist drug] | Restricted | ||||
| Powder and solvent for solution for injection | |||||
| Melphalan (Non-proprietary) | Restricted | ||||
| mercaptopurine | On Formulary | ||||
| methotrexate | On Formulary | ||||
| Oral solution | |||||
| Methotrexate (Non-proprietary) | Non Formulary | ||||
| Solution for injection | |||||
| Methotrexate (Non-proprietary) | Restricted | ||||
| Metoject PEN (medac UK) | Non Formulary | ||||
| Nordimet (Nordic Pharma Ltd) | Non Formulary | ||||
| Zlatal (Nordic Pharma Ltd) | Non Formulary | ||||
| Solution for infusion | |||||
| Methotrexate (Non-proprietary) | Restricted | ||||
| mitomycin [Specialist drug] | Restricted | ||||
| Powder for solution for injection | |||||
| Mitomycin (Non-proprietary) | Restricted | ||||
| mitotane [Specialist drug] | Non Formulary | ||||
| mitoxantrone [Specialist drug] | Restricted | ||||
| Solution for infusion | |||||
| Onkotrone (Baxter Healthcare Ltd) | Restricted | ||||
| nelarabine [Specialist drug] | Non Formulary | ||||
| Solution for infusion | |||||
| Atriance (Sandoz Ltd) | Non Formulary | ||||
| oxaliplatin [Specialist drug] | Restricted |
NICE TA100 NICE TA93 |
|||
| Solution for infusion | |||||
| Oxaliplatin (Non-proprietary) | Restricted | ||||
| paclitaxel [Specialist drug] | Restricted |
NICE TA55 NICE TA284 NICE TA389 NICE TA476 |
|||
| Solution for infusion | |||||
| Paclitaxel (Non-proprietary) | Restricted | ||||
| pemetrexed [Specialist drug] | Non Formulary |
NICE TA124 NICE TA181 NICE TA402 NICE TA190 NICE TA135 |
|||
| pentostatin [Specialist drug] | Restricted | ||||
| Powder for solution for injection | |||||
| Nipent (Pfizer Ltd) | Restricted | ||||
| procarbazine [Specialist drug] | Restricted | ||||
| raltitrexed [Specialist drug] | Non Formulary | ||||
| tegafur with gimeracil and oteracil [Specialist drug] | Non Formulary | ||||
| temozolomide [Specialist drug] | Non Formulary |
NICE TA23 NICE TA121 |
|||
| thiotepa [Specialist drug] | Restricted | ||||
| tioguanine [Specialist drug] | Restricted | ||||
| topotecan [Specialist drug] | Non Formulary |
NICE TA183 NICE TA184 NICE TA389 |
|||
| Solution for infusion | |||||
| Topotecan (Non-proprietary) | Non Formulary | ||||
| trabectedin [Specialist drug] | Non Formulary |
NICE TA185 NICE TA389 |
|||
| treosulfan [Specialist drug] | Restricted |
NICE TA640 |
|||
| Powder for solution for injection | |||||
| Treosulfan (Non-proprietary) | Restricted | ||||
| tretinoin [Specialist drug] | Restricted | ||||
| vinblastine sulfate [Specialist drug] | Restricted | ||||
| Solution for injection | |||||
| Vinblastine sulfate (Non-proprietary) | Restricted | ||||
| vincristine sulfate [Specialist drug] | Restricted | ||||
| Solution for injection | |||||
| Vincristine sulfate (Non-proprietary) | Restricted | ||||
| vindesine sulfate [Specialist drug] | Restricted | ||||
| Powder for solution for injection | |||||
| Eldisine (Genus Pharmaceuticals Ltd) | Restricted | ||||
| vinorelbine [Specialist drug] | Non Formulary | ||||
| Solution for infusion | |||||
| Vinorelbine (Non-proprietary) | Non Formulary | ||||
| Navelbine (Pierre Fabre Ltd) | Non Formulary | ||||
| Malignant disease / Cytotoxic drug-induced side effects | |||||
| dexrazoxane | Non Formulary | ||||
| Powder and solvent for solution for infusion | |||||
| Savene (CNX Therapeutics Ltd) | Non Formulary | ||||
| folinic acid | On Formulary |
NICE TA212 |
|||
| Solution for injection | |||||
| Folinic acid (Non-proprietary) | On Formulary | ||||
| Sodiofolin (medac UK) | Non Formulary | ||||
| levofolinic acid | Non Formulary | ||||
| Solution for injection | |||||
| Isovorin (Pfizer Ltd) | Non Formulary | ||||
| mesna | Restricted | ||||
| Solution for injection | |||||
| Mesna (Non-proprietary) | Restricted | ||||
| Malignant disease / Hyperuricaemia associated with cytotoxic drugs | |||||
| allopurinol | On Formulary | ||||
| febuxostat | Restricted |
NICE TA164 |
|||
| rasburicase | Restricted | ||||
| Powder and solvent for solution for infusion | |||||
| Fasturtec (Sanofi) | Restricted | ||||
| Malignant disease / Hormone responsive malignancy | |||||
| abiraterone acetate | Non Formulary |
NICE TA259 NICE TA387 NICE TA721 |
|||
| bicalutamide | Restricted | ||||
| buserelin | Non Formulary | ||||
| Solution for injection | |||||
| Suprefact (Neon Healthcare Ltd) | Non Formulary | ||||
| Spray | |||||
| Suprecur (Neon Healthcare Ltd) | Non Formulary | ||||
| cyproterone acetate | On Formulary | ||||
| degarelix | Restricted |
NICE TA404 |
|||
| Powder and solvent for solution for injection | |||||
| Firmagon (Ferring Pharmaceuticals Ltd) | Restricted | ||||
| diethylstilbestrol | Restricted | ||||
| ethinylestradiol | On Formulary | ||||
| flutamide | On Formulary | ||||
| goserelin | Restricted | ||||
|
Note
As per IMOC (June 2021)- AMBER 2 Specialist Initiation, stabilisation for 1-3 months (depending on product), then continuation in primary care under an individual management plan |
|||||
| lanreotide | Restricted | ||||
| leuprorelin acetate | Non Formulary | ||||
| medroxyprogesterone acetate | On Formulary | ||||
| Suspension for injection | |||||
| Depo-Provera (Pfizer Ltd) | Non Formulary | ||||
| Sayana Press (Pfizer Ltd) | Non Formulary | ||||
| megestrol acetate | On Formulary | ||||
| Oral suspension | |||||
| Megestrol acetate (Non-proprietary) | Non Formulary | ||||
| norethisterone | On Formulary | ||||
| Solution for injection | |||||
| Noristerat (Bayer Plc) | Non Formulary | ||||
| octreotide | Restricted | ||||
| Solution for injection | |||||
| Octreotide (Non-proprietary) | Restricted | ||||
| Sandostatin (Novartis Pharmaceuticals UK Ltd) | Non Formulary | ||||
| Powder and solvent for suspension for injection | |||||
| Sandostatin LAR (Novartis Pharmaceuticals UK Ltd) | Restricted | ||||
| triptorelin | Restricted | ||||
| Malignant disease / Hormone responsive breast cancer | |||||
| anastrozole | On Formulary | ||||
| exemestane | On Formulary | ||||
| fulvestrant | Non Formulary |
NICE TA503 |
|||
| Solution for injection | |||||
| Faslodex (AstraZeneca UK Ltd) | Non Formulary | ||||
| letrozole | On Formulary | ||||
| tamoxifen | On Formulary | ||||
| Oral solution | |||||
| Tamoxifen (Non-proprietary) | Non Formulary | ||||
| toremifene | Non Formulary | ||||
| Malignant disease / Photodynamic therapy responsive malignancy | |||||
| temoporfin [Specialist drug] | Non Formulary | ||||
| Solution for injection | |||||
| Foscan (Biolitec Pharma Ltd) | Non Formulary | ||||
| Malignant disease / Secondary bone metastases and hypercalcaemia | |||||
| calcitonin (salmon) | On Formulary | ||||
| Solution for injection | |||||
| Calcitonin (salmon) (Non-proprietary) | On Formulary | ||||
| denosumab | Non Formulary |
NICE TA204 NICE TA265 |
|||
| Solution for injection | |||||
| Prolia (Amgen Ltd) | Non Formulary | ||||
| Xgeva (Amgen Ltd) | Non Formulary | ||||
| ibandronic acid | Non Formulary |
NICE TA464 |
|||
| Solution for injection | |||||
| Ibandronic acid (Non-proprietary) | Non Formulary | ||||
| Bonviva (Atnahs Pharma UK Ltd) | Non Formulary | ||||
| Solution for infusion | |||||
| Ibandronic acid (Non-proprietary) | Non Formulary | ||||
| Bondronat (Atnahs Pharma UK Ltd) | Non Formulary | ||||
| pamidronate disodium | On Formulary | ||||
| Solution for infusion | |||||
| Pamidronate disodium (Non-proprietary) | On Formulary | ||||
| sodium clodronate | On Formulary | ||||
| zoledronic acid | On Formulary |
NICE TA464 |
|||
| Infusion | |||||
| Aclasta (Sandoz Ltd) | Non Formulary | ||||
| Zometa (Phoenix Labs Ltd) | Non Formulary | ||||
| Solution for infusion | |||||
| Zoledronic acid (Non-proprietary) | On Formulary | ||||
| Zometa (Phoenix Labs Ltd) | Non Formulary | ||||